Researchers presented findings at a European lung meeting, revealing that patients using semaglutide, marketed as Ozempic and Wegovy, experienced a significant reduction in asthma attacks compared to those on traditional diabetes treatments. The study, based on UK records, found that individuals with asthma who began semaglutide therapy had nearly 40% fewer attacks than similar patients on older diabetes medications. The drug, originally developed for diabetes management, has shown unexpected benefits in respiratory health.
The results suggest a potential new role for semaglutide in asthma treatment, though further research is needed to confirm these findings. The study highlights the growing interest in repurposing existing medications for conditions beyond their original intended use. While the data is promising, experts caution that more long-term studies are necessary before recommending semaglutide as a standard treatment for asthma.
The European lung meeting, where the study was presented, has drawn attention to the possible link between diabetes drugs and respiratory health. As more research emerges, healthcare professionals may consider semaglutide as a potential adjunct therapy for asthma patients. The findings could influence future treatment guidelines and open new avenues for drug development.
